INTRODUCTION {#s1}
============

Breast cancer is one of the most common malignant tumors, and now it is becoming a leading cause of cancer-related death in women worldwide \[[@R1]--[@R2]\]. The treatment for breast cancer involves a combination of surgery, chemotherapy, and radiotherapy \[[@R3]\]. Over the past decades, the mortality rate among breast cancer patients has decreased. However, cardiotoxicity induced by the chemotherapy has become a leading cause of morbidity and mortality in survivors \[[@R4]--[@R5]\]. To prevent heart failure caused by cancer therapy, consideration of potential cardiotoxicity is very important.

Epirubicin and therarubicin, as common anthracyclines, are widely used chemotherapy drugs for reducing the recurrence of breast cancer in China. However, the use of these drugs is limited by their cardiotoxicity. The cardiotoxicity of anthracycline-based chemotherapy may be associated with the cumulative dose, other associated cytotoxic drugs, or the advanced age of patients \[[@R6]--[@R7]\]. Previous studies found that the cardiotoxicity can appear during or after the chemotherapy in breast cancer patients \[[@R6], [@R8]\]. Left ventricular ejection fraction (LVEF) measurement by two-dimensional echocardiography is the most commonly used method for detecting cardiotoxicity, which is most commonly defined as a ≥5% or ≥10% reduction in the LVEF from baseline to an LVEF \<55% in symptomatic patients and asymptomatic patients, respectively \[[@R9]\]. However, the use of LVEF has limitations for early detection of cardiotoxicity because it cannot reflect the early dysfunction of the heart \[[@R5]\].

With the development of various imaging techniques, such as tissue Doppler imaging (TDI), speckle tracking echocardiography (STE, two-dimensional or three-dimensional), and cardiac magnetic resonance imaging (CMRI), the cardiotoxicity of anthracycline-based chemotherapy can be detected with greater convenience. However, the angle dependency of TDI makes these results difficult to reproduce \[[@R10]\]. Although CMRI is considered the gold standard for evaluating LV volumes and EF, its lack of availability and high cost limit its routine use \[[@R11]--[@R12]\]. STE is an ideal method for detecting cardiotoxicity caused by chemotherapy, and previous studies have demonstrated that STE is feasible and convenient for early detection of cardiac dysfunction \[[@R13]--[@R15]\].

The aim of the present study was to identify a parameter for reliable detection of cardiac dysfunction via STE after chemotherapy in breast cancer patients. We hypothesed that longitudinal rotation (LR) motion could be detected in the hearts of breast cancer patients after chemotherapy, then tested the hypothesis by measuring the global peak systolic LR (PSLR) degrees in breast cancer patients after anthracycline-based chemotherapy. Cardiac dysfunction was then evaluated to confirm whether LR could serve as a new way to detect cardiac dysfunction after chemotherapy in breast cancer patients.

RESULTS {#s2}
=======

General characteristics of the patients {#s2_1}
---------------------------------------

The general characteristics of the study group are listed in Table [1](#T1){ref-type="table"}. The cumulative dose of epirubicin given was significantly higher than that of therarubicin.

###### Baseline characteristics of the total population (mean±SD)

  Variable                                     Baseline
  -------------------------------------------- ------------------------------
  Age (yrs)                                    49±8
  Female                                       43(43)
  Body surface area (m^2^)                     1.65±0.12
  Systolic blood pressure(mmHg)                121±11
  Diastolic blood pressure (mmHg)              76±9
  Heart rate (bpm)                             77±3
  Side of breast cancer                        
  Left                                         22(43)
  Right                                        21(43)
  Both                                         0(43)
  Cardiovascular risk factors                  
   Diabetes                                    0(43)
   Hypertension                                0(43)
   Hyperlipidemia                              0(43)
   Smoking history                             0(43)
  Cumulative dose of anthracycline (mg/m^2^)   
   Epirubicin (27)                             524±141\* (95 % CI: 479-634)
   Therarubicin (16)                           336±115 (95 % CI: 275-398)
  Chemotherapy                                 
   FEC(5-FU, EPI/ THP, CTX)                    30(43)
    5-FU, EPI, CTX                             17(30)
    5-FU, THP, CTX                             13 (30)
   TEC(TXT, EPI/ THP, CTX)                     13(43)
    TXT, EPI, CTX                              10 (13)
    TXT, THP, CTX                              3 (13)

5-FU: 5-flourouracil; EPI: epirubicin; THP: therarubicin; CTX: cyclophosphamide; TXT: taxotere.

The values at baseline compared with those at 3 weeks after the final cycle of chemotherapy, \*P\<0.05.

Conventional two-dimensional echocardiographic parameters of the study groups {#s2_2}
-----------------------------------------------------------------------------

The conventional two-dimensional echocardio-graphic parameters of the study groups at the three time points are listed in Table [2](#T2){ref-type="table"}. There were no significant differences among the study groups at the three separate time points, except that the e'~sep~ at baseline was higher than at 3 weeks and 6 months after the final cycle of chemotherapy. Although there were no significant differences among E, E/A, and e'~lat~ between the groups, the baseline values were higher than those at 3 weeks and 6 months after the final cycle of chemotherapy.

###### Conventional two-dimensional echocardiographic parameters, speckle-tracking echocardiographic parameters and segmental and global peak systolic longitudinal rotation (PSLR) of the total population at baseline and 3 weeks and 6 months after the final cycle of chemotherapy (mean±SD)

  Variable                                                    Baseline              3 weeks          6 months        P-value                   
  ----------------------------------------------------------- --------------------- ---------------- --------------- ------------- ----------- -----------
  Conventional two-dimensional echocardiographic parameters   IVSd(mm)              8.93±0.99        8.67±0.78       8.72±0.80     0.342       
                                                              LVDd(mm)              44.98±3.03       45.63±2.95      45.95±3.07    0.314       
                                                              LVPWd(mm)             8.67±1.06        8.56±0.73       8.79±0.86     0.487       
                                                              LVSd(mm)              29.74±2.73       30.56±2.77      30.67±2.09    0.187       
                                                              LVEDV(ml)             61.44±13.77      64.35±13.38     64.37±13.48   0.516       
                                                              LVESV(ml)             22.23±6.41       23.12±7.57      23.42±6.79    0.723       
                                                              LVEF(%)               63.47±6.31       63.35±5.88      63.72±6.49    0.961       
                                                              E(m/s)                0.71±0.16        0.65±0.14       0.66±0.17     0.180       
                                                              A(m/s)                0.66±0.13        0.69±0.17       0.69±0.15     0.556       
                                                              E/A                   1.13±0.39        0.99±0.32       1.01±0.36     0.144       
                                                              e'~Sep~               0.09±0.02\*      0.07±0.02       0.08±0.02     **0.022**   
                                                              a'~Sep~               0.10±0.02        0.10±0.02       0.10±0.02     0.633       
                                                              e'~lat~               0.13±0.03        0.12±0.03       0.11±0.03     0.062       
                                                              a'~lat~               0.10±0.02        0.10±0.03       0.10±0.02     0.903       
                                                              E/e'~sep~             5.73±1.68        5.75±1.84       6.17±2.04     0.469       
                                                              E/e'~lat~             8.78±2.64        9.27±2.38       9.15±2.72     0.660       
  Speckle-tracking echocardiographic parameters               Peak velocity(cm/s)   Systolic         3.60±0.95       3.37±1.34     3.31±0.71   0.391
                                                              Early-diastolic       -4.48±1.33\*\#   -3.97±1.15      -3.81±1.09    **0.028**   
                                                              Late-diastolic        -3.82±0.94       -3.78±0.83      -3.74±0.88    0.912       
  Peak systolic strain(%)                                     Endomyocardium        -24.98±3.67      -23.73±6.32     -24.20±6.32   0.451       
                                                              Midmyocardium         -21.25±3.04      -20.76±2.48     -20.37±2.68   0.333       
                                                              epimyocardium         -18.59±2.61      -18.21±2.57     -17.63±2.28   0.206       
  Peak strain rate(S^-1^)                                     Systolic              -1.30±0.21       -1.16±0.48      -1.21±0.17    0.139       
                                                              Early-diastolic       1.76±0.37        1.65±0.35       1.63±0.39     0.238       
                                                              Late-diastolic        1.19±0.30        1.45±1.67       1.17±0.30     0.335       
  Peak systolic Displacement (mm)                             9.79±1.82             8.72±5.06        9.21±1.53       0.308                     
  PSLR                                                        4-CH                  Lateral wall     9.30±2.73\*\#   7.00±4.08     6.83±4.42   **0.005**
  Septal wall                                                 -8.12±3.06            -8.87±2.90       -8.75±2.72      0.438                     
  Apex wall                                                   1.51±3.34             -0.14±4.03       -0.14±3.78      0.064                     
  Global                                                      -0.23±3.26\*\#        -1.91±3.27       -1.90±2.92      **0.020**                 

IVSd: interventricular septal thickness in end-diastolic period, LVDd: left ventricular diameter in end-diastolic period, LVPWd: left ventricular posterior wall thickness in end-diastolic period, LVSd: left ventricular diameter in end-diastolic period, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic volume, LVEF: left ventricular ejection fraction, E: peak velocity during early diastole of anterior mitral leaflet, A: peak velocity during late diastole of anterior mitral leaflet, e'~Sep~: peak early diastolic annular velocities at septum positions using TDI, a'~Sep~: peak late diastolic annular velocities at septum positions using TDI, e'~lat~: peak early diastolic annular velocities at lateral positions using TDI, a'~lat~: peak late diastolic annular velocities at lateral positions using TDI. 4-CH: Apical 4- chamber view

The values at baseline compared with those at 3 weeks after the final cycle of chemotherapy, \*P\<0.05.

The values at baseline compared with those at 6 weeks after the final cycle of chemotherapy, \#P\<0.05.

"+" indicates counter-clockwise rotation and "-" indicates clockwise rotation.

STE parameters {#s2_3}
--------------

The STE parameters of the study groups at the three time points are listed in Table [2](#T2){ref-type="table"}. The peak early-diastole LV wall velocity at baseline was significantly higher than at 3 weeks and 6 months after the final cycle of chemotherapy (Figure [1](#F1){ref-type="fig"}). Although there were no significant differences among the peak systolic longitudinal strains of the different myocardial layers, the values at baseline were higher than those at 3 weeks and 6 months after the final cycle of chemotherapy (Figure [2A](#F2){ref-type="fig"}, [2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). There were no differences among the peak longitudinal strain rates and displacements.

![Peak early-diastole LV wall velocities at baseline and 3 weeks and 6 months after the final cycle of chemotherapy\
The peak early-diastole LV wall velocity at baseline was significantly higher than at 3 weeks and 6 months after the final cycle of chemotherapy.](oncotarget-08-70072-g001){#F1}

![Bulls eye diagrams of the peak systolic strain of LV in the subendocardial, midmyocardial, and subepicardial layers at three time points **(A, B, C)**. (A) At baseline, (B) 3 weeks after the final cycle of chemotherapy, and (C) 6 months after the final cycle of chemotherapy. Global PSLR in breast cancer patients at three separate time points **(D, E, F)**. (D) At baseline, (E) 3 weeks after the final cycle of chemotherapy, and (F) 6 months after the final cycle of chemotherapy. PSLR: peak systolic longitudinal rotation.](oncotarget-08-70072-g002){#F2}

Segmental and global PSLR {#s2_4}
-------------------------

The segmental and global PSLR values of the study groups at the three time points are shown in Table [2](#T2){ref-type="table"}. In the apical 4-chamber view, the lateral wall rotated counter-clockwise, whereas the septal wall rotated clockwise. The global PSLR at baseline was small, and significant differences were detected between the lateral wall and global PSLR values at baseline and those at 3 weeks and 6 months after the final cycle of chemotherapy (Figure [2D](#F2){ref-type="fig"}, [2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). The absolute value of the lateral wall PSLR at baseline was higher than the values at 3 weeks and 6 months after the final cycle of chemotherapy (Figure [3A](#F3){ref-type="fig"}), whereas the absolute value of the global PSLR at baseline was lower than the values at 3 weeks and 6 months after the final cycle of chemotherapy (Figure [3B](#F3){ref-type="fig"}). The values of the lateral wall and global PSLR did not change significantly from 3 weeks to 6 months after the final cycle of chemotherapy.

![Lateral wall **(A)** and global PSLR **(B)** at baseline and 3 weeks and 6 months after the final cycle of chemotherapy. The absolute value of the lateral wall PSLR was higher at baseline than at 3 weeks and 6 months after the final cycle of chemotherapy, while the absolute value of the global PSLR at baseline was lower than at 3 weeks and 6 months after the final cycle of chemotherapy.](oncotarget-08-70072-g003){#F3}

Correlations between the global PSLR and LVEF, E, A, E/A, e'~sep~, a'~sep~, e'~lat~, a'~lat~, E/ e'~sep~, E/ e'~lat~ and cumulative dose of anthracycline {#s2_5}
---------------------------------------------------------------------------------------------------------------------------------------------------------

The results of correlation tests are listed in Table [3](#T3){ref-type="table"}. At baseline, no correlation was found between the global PSLR and LVEF, E, A, E/A, e'~sep~, a'~sep~, e'~lat~, a'~lat~, E/ e'~sep~ and E/ e'~lat~.However, at 3 weeks after the final cycle of chemotherapy, the global PSLR was positively correlated with the e'~lat~. Breast cancer patients with a higher e'~lat~ were more likely to have a higher global PSLR (Figure [4A](#F4){ref-type="fig"}). At 6 months after the final cycle of chemotherapy, the global PSLR was positively correlated with e'~sep~ and e'~lat~, and negatively correlated with E/e'~sep~ and E/e'~lat~. Breast cancer patients with a higher e'~sep~ and e'~lat~ and lower E/e'~sep~ and E/e'~lat~ were more likely to have a higher global PSLR (Figure [4B](#F4){ref-type="fig"}, [4C](#F4){ref-type="fig"}, [4D](#F4){ref-type="fig"} and [4E](#F4){ref-type="fig"}).

###### Correlations between global PSLR and 2D, Doppler values and cumulative dose of anthracycline.

                    Global PSLR                                         
  ----------------- ------------- ------- -------- ----------- -------- -------------
  LVEF              0.075         0.634   -0.211   0.175       -0.233   0.133
  E                 -0.01         0.950   -0.038   0.811       -0.110   0.481
  A                 -0.214        0.169   -0.046   0.770       -0.273   0.076
  E/A               0.155         0.322   0.044    0.779       0.078    0.617
  e'~Sep~           0.261         0.091   0.140    0.372       0.392    **0.009**
  a'~Sep~           -0.116        0.458   -0.258   0.095       -0.202   0.193
  e'~lat~           0.291         0.058   0.320    **0.037**   0.559    **\<0.001**
  a'~lat~           0.094         0.548   -0.099   0.529       0.014    0.929
  E/e'~sep~         -0.272        0.078   -0.169   0.280       -0.508   **0.001**
  E/e'~lat~         -0.202        0.194   -0.258   0.070       -0.580   **\<0.001**
  Cumulative dose                         -0.180   0.248       -0.147   0.347

![Correlation between global PSLR and e'~lat~ at 3 weeks after the final cycle of chemotherapy\
Global PSLR positively correlated with the e'~lat~ at 3 weeks, and thus, breast cancer patients with a higher e'~lat~ at 3 weeks after the final chemotherapy cycle may have a higher global PSLR **(A)**. Correlations between global PSLR and e'~sep~, e'~lat~, E/e'~sep~, and E/e'~lat~ at 6 months after the final cycle of chemotherapy. Global PSLR positively correlated with e'~sep~ and e'~lat~ and negatively correlated with E/e'~sep~ and E/e'~lat~. Breast patients with a higher e'~sep~ and e'~lat~, and lower E/e'~sep~ and E/e'~lat~ may have a higher global PSLR **(B, C, D, E)**. ROC analysis for determining the accuracy of PSLR for identifying cardiac dysfunction in breast cancer patients. The sensitivity and specificity for a PSLR cut-off value of -2.58° at 3 weeks after the final cycle of chemotherapy were 55.8% and 72.1%, respectively, with an area under the ROC curve of 0.649 **(F)**. At 6 months after the final cycle of chemotherapy, these values were 67.4% and 60.5% for a PSLR, cut-off value of -1.50°, with an area under the ROC curve of 0.665 **(G)**.](oncotarget-08-70072-g004){#F4}

ROC analysis for detecting the accuracy of PSLR for detecting cardiotoxicity in breast cancer patients {#s2_6}
------------------------------------------------------------------------------------------------------

The areas under ROC curves (AUCs) were measured to determine the cut-off values for the global PSLR with the optimal sensitivity, specificity, and accuracy for assessing cardiotoxicity with regard to LV function. The AUC values at 3 weeks and 6 months after the final cycle of chemotherapy in breast cancer patients were 0.649 and 0.665, respectively. The optimal cut-off values for global PSLR at 3 weeks and 6 months after the final cycle of chemotherapy were -2.58° and -1.50°, respectively. The sensitivity and specificity for the global PSLR at 3 weeks after the final cycle of chemotherapy were 55.8% and 72.1%, respectively, and the corresponding values at 6 months after the final cycle of chemotherapy were 67.4% and 60.5%, respectively (Figure [4F](#F4){ref-type="fig"} and [4G](#F4){ref-type="fig"}).

Differing effects of epirubicin-based and therarubicin-based chemotherapy {#s2_7}
-------------------------------------------------------------------------

The STE parameters of patients who received epirubicin-based chemotherapy are compared to those of patients who received therarubicin-based chemotherapy in Table [4](#T4){ref-type="table"}. In the group that received epirubicin-based chemotherapy, the peak early-diastole LV wall velocity, and lateral wall and global PSLR differed significantly among the three time points; however, these values did not change significantly over time after therarubicin-based chemotherapy. The absolute value of the peak early-diastole LV wall velocity and the lateral wall PSLR at baseline were higher than those at 3 weeks and 6 months after the final cycle of chemotherapy, whereas the absolute value of global PSLR at baseline were lower than the values at 3 weeks and 6 months after the final cycle of chemotherapy in both the epirubicin-based and therarubicin-based chemotherapy groups. The values of these parameters did not differ significantly between 3 weeks and 6 months after the final cycle of chemotherapy (Figure [5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}).

###### Detection of differences in epirubicin-based cardiotoxicity and therarubicin-based cardiotoxicity (mean±SD)

  Variable                                 Epirubicin       Therarubicin                                                                   
  ---------------------------------------- ---------------- -------------- ------------ ----------- ------------ ------------ ------------ -------
  Velocity (peak early-diastolic) (cm/s)   -4.69±1.22\*\#   -3.97±1.05     -3.76±1.02   **0.007**   -4.13±1.49   -3.97±1.35   -3.90±1.22   0.128
  Lateral wall PSLR (°)                    9.55±2.93\*\#    7.25±3.67      6.37±4.38    **0.007**   8.87±2.39    6.58±4.78    7.60±4.53    0.286
  Global PSLR (°)                          -0.34±3.51\*     -2.41±3.18     -2.04±2.80   **0.044**   -0.04±2.88   -1.07±3.33   -1.67±3.19   0.344

![Differences in peak early-diastole LV wall velocity **(A)** and lateral wall **(B)** and global PSLR **(C)** after epirubicin-based chemotherapy versus therarubicin-based chemotherapy at baseline and 3 weeks and 6 months after the final cycle of chemotherapy. The absolute values of the peak early-diastole LV wall velocity and the lateral wall PSLR at baseline were higher than those at 3 weeks and 6 months after the final cycle of chemotherapy, whereas the absolute value of global PSLR at baseline was lower than at 3 weeks and 6 months after the final cycle of chemotherapy in both epirubicin-based and therarubicin-based chemotherapy groups.](oncotarget-08-70072-g005){#F5}

Reproducibility and repeatability {#s2_8}
---------------------------------

The results for the intraobserver and interobserver variabilities for the global PSLR upon repeated measurements in all study patients are shown in Table [5](#T5){ref-type="table"}.

###### Interobserver and intraobserver reproducibility and repeatability

  Variable   Global PSLR(°)                              
  ---------- ---------------- ------------- ------------ --------------
  Baseline   -0.19±0.49       -1.18∼0.80    -0.19±0.48   -1.16∼0.78
  3 weeks    -1.99±0.51       -3.02∼-0.96   -1.87±0.50   -2.89∼ -0.86
  6 months   -1.96±0.45       -2.86∼-1.05   -1.90±0.44   -2.79∼-1.01

DISCUSSION {#s3}
==========

As is well known, chemotherapy can reduce the recurrence of breast cancer, especially when used in combination with anthracyclines. However, the cardiotoxicity of anthracyclines is becoming a major concern. Early detection of cardiotoxicity is becoming increasingly important. The main findings of this study were: ① cardiac diastolic and systolic dysfunction was found in breast cancer patients after anthracycline-based chemotherapy; ② LR motion is a new parameter for detecting cardiotoxicity at 3 weeks and 6 months after the final cycle of chemotherapy; and ③ subgroup analysis indicated that the cardiotoxicity of epirubicin-based chemotherapy maybe stronger than that of therarubicin-based chemotherapy.

In clinical practice, LVEF is quantified as a measure of cardiac function. In the present study, we found that there were no significant differences in LVEF among the three time points. Thus, LVEF cannot be used in clinical practice for early detection of cardiotoxicity. With its angle independency and high reproducibility, STE is widely used for detection of cardiac function \[[@R16]--[@R18]\]. Ho et al \[[@R19]\] used STE to examine the long-term effects of standard chemotherapy on myocardial function in asymptomatic breast cancer survivors and found that the E/A ratio, global E', and global longitudinal 2D strain were reduced in comparison with those of controls. Fallah-Rad et al \[[@R3]\] used cardiac biomarkers, tissue velocity (TVI), strain imaging, and CMRI to predict early LV dysfunction in breast cancer patients treated with adjuvant trastuzumab therapy. They found that the peak global longitudinal and radial strain decreased early in the group with trastuzumab-mediated cardiotoxicity. Portugal et al \[[@R16]\] used speckle tracking imaging to determine the relationship between global and regional longitudinal strain (GLS) and chemotherapy-induced cardiotoxicity in breast cancer patients and concluded that impaired GLS in patients with preserved LVEF was independently associated with an increased incidence of chemotherapy-induced cardiotoxicity. Our results were consistent with those of this previous research. Cardiac diastolic and systolic dysfunction was found after administration of anthracycline-based chemotherapy, based on lower values of e'~Sep~, peak early-diastolic LV wall velocity, and longitudinal strain in different myocardial layers at 3 weeks and 6 months after the final cycle of chemotherapy in comparison with the baseline values. The reasons for these results may be related to LV wall stress and local differences in the activation of signaling pathways involved in apoptosis or fibrosis.

LR, was first reported by Popović \[[@R20]\], represents the rotational motion in the long axis of the heart. In ischemic cardiomyopathy, dilated cardiomyopathy, and hypertension patients, as well as in acute myocardial ischemia animals, LR motion in the heart has been reported \[[@R21]--[@R23]\]. A normal myocardial fiber consists of longitudinal and circumferential fibers. Subendocardial and subepicardial myocardium are mainly composed of longitudinal fibers, and the middle layer is composed of circumferential fibers \[[@R24]\]. During systole and diastole, two motions are produced: short and long axis motions. In systole, when viewed from the apex, the apex rotates counter-clockwise, while the base rotates clockwise. This twisting motion of the left ventricle can be described as ''the wringing of a linen cloth to squeeze out water'' \[[@R15]\]. When viewed from its long axis, in systole, shortening of the long axis and thickening of the walls can be observed.

Previous studies indicated that the degree of PSLR in a normal heart is small, and our results agree with this \[[@R21]--[@R23]\]. The global PSLR at baseline in our study was -0.23±3.26°. At 3 weeks and 6 months after the final cycle of chemotherapy, the absolute values were higher than that at baseline. However, the value of the lateral wall PSLR at baseline was lower than those at 3 weeks and 6 months after the final cycle of chemotherapy. These results may demonstrate systolic dysfunction after anthracycline-based chemotherapy. The reason for such LR may be related to changes in the fiber arrangement by 3 weeks and 6 months after the final cycle of chemotherapy. Anthracyclines induce the formation of reactive oxygen species, which in excess can result in DNA and cytosolic damage, with subsequent loss of cellular integrity and apoptosis, inducing disarray and imbalance of the myocardial fibers \[[@R25]\].

In the present study, no correlations were found between the baseline values of global PSLR and LVEF, E, A, E/A, e'~sep~, a'~sep~, e'~lat~, a'~lat~, E/e'~sep~, E/e'~lat~ and cumulative dose of anthracycline. At 3 weeks after the final cycle of chemotherapy, breast patients with a higher e'~lat~ were more likely to have a higher global PSLR. At 6 months after the final cycle of chemotherapy, breast patients with higher e'~sep~ and e'~lat~ and lower E/e'~sep~ and E/e'~lat~ values were more likely to have a higher global PSLR. These findings indicated that although the LV filling pressure did not differ among the three time points, a lower LV filling pressure may correspond to a higher global PSLR.

The AUC values for PSLR at 3 weeks and 6 months after the final cycle of chemotherapy in breast cancer patients were 0.649 and 0.665, respectively. The sensitivity and specificity values for a PSLR cut-off value of -2.58° at 3 weeks after the final cycle of chemotherapy were 55.8% and 72.1%, respectively, and those for a PSLR cut-off value of -1.50° at 6 months after the final cycle of chemotherapy were 67.4% and 60.5%, respectively. From these results, we found that use of the global PSLR to detect cardiotoxicity after anthracycline-based chemotherapy was reliable.

When we compared parameters of cardiac function between the patients who received epirubicin-based and therarubicin-based chemotherapy, we found that after epirubicin-based chemotherapy, the peak early-diastole LV wall velocity and lateral wall and global PSLR differed significantly among the three time points. However, no differences between the time points were observed in patients who received therarubicin-based chemotherapy. The absolute values of peak early-diastole LV wall velocity and the lateral wall PSLR at baseline were higher than those at 3 weeks and 6 months after the final cycle of chemotherapy, whereas the absolute value of global PSLR at baseline was lower than those at 3 weeks and 6 months after the final cycle of chemotherapy, in both the epirubicin-based and therarubicin-based chemotherapy groups. From this, we found that the cardiotoxicity of epirubicin-based chemotherapy may be stronger than that of therarubicin-based chemotherapy.

Finally, the lack of significant differences in the values of cardiac function parameters between 3 weeks and 6 months after the final cycle of chemotherapy illustrated that the anthracycline-induced cardiotoxicity is irreversible. But to state this surely, more breast cancer patients should be increased and also it needs longer follow up.

MATERIALS AND METHODS {#s4}
=====================

Study sample {#s4_1}
------------

This study was approved by the ethics committee of ChangZhou No. 2 People's Hospital, affiliated to NanJing Medical University. All patients provided consent for participation in the study.

Forty-three female breast cancer patients were enrolled. The inclusion criteria were: ① treatment with epirubicin or therarubicin; and ② LVEF \>50%. None of the patients had a history of cardiovascular disease, hypertension, or diabetes mellitus, all of them were asymptomatic before the chemotherapy; and ③ All enrolled breast cancer patients did not perform radiotherapy.

In total, the patients were evaluated at three separate time points: ① baseline: 1--3 days before the initiation of anthracycline-based chemotherapy; ② 3 weeks after the final cycle of chemotherapy; and ③ 6 months after the final cycle of chemotherapy.

Conventional 2D echocardiography {#s4_2}
--------------------------------

At each visit, all patients underwent conventional 2D echocardiography (Vivid E9, GE Healthcare). Interventricular septum thickness at end-diastole (IVSd), LV posterior wall thickness in end-diastole (LVPWd), and LV diameter at end-diastole (LVDd) and end-systole (LVSd) were measured in the parasternal long axis view of the LV by M-mode. Biplane Simpson's method was used to measure the LV end-diastolic and systolic volume (LVEDV and LVESV) for calculation of the LVEF. The peak early and late diastolic mitral annular velocities (E and A, respectively) were measured by pulsed-wave Doppler, and the ratio of E/A was calculated. The peak early (e') and late (a') diastolic annular velocities were obtained at the septum (e'~sep~) and lateral (e'~lat~) positions using TDI, and E/ e'~sep~ and E/ e'~lat~ were measured.

In each group, ECG leads were connected to the patients. For offline analysis, the standard high frame rate (\>36 /s) of the apical 3-, 4-, and 2-chamber views of three consecutive cycles were measured while patients held their breath.

Analysis of LV function {#s4_3}
-----------------------

The apical 3-, 4-, and 2- chamber views were analyzed using 2D-STE software (2D-Strain, EchoPac PC 113, GE Healthcare, Horten, Norway) by one experienced cardiologist. The peak systolic and diastolic longitudinal velocities and strain rates as well as the peak systolic longitudinal strain of three different layers and displacement of LV were measured.

We defined LR as the global rotation of the LV cross section. Using the SAX-MV option of the Echopac in the apical 4-chamber view, the subendocardial layer was displayed. The software automatically created a region of interest (ROI) that included the subendocardial, midmyocardial, and subepicardial layers. The LV region was divided into five segments: base-septal, middle-septal, apex, middle-lateral, and base-lateral. The segmental and global PSLR of the LV was assessed via the software.

Statistical analysis {#s4_4}
--------------------

All data analyses were performed using SPSS 17.0 software (SPSS, Chicago, IL, USA). Data are presented as the mean ± standard deviation (SD). Any difference was considered statistically significant in all tests when the P-value was \<0.05. Kolmogorov-Smirnov's test was used to detect the normality of all the values. Differences among the values at the three separate time points were compared with one-way analysis of variance. Comparisons of two samples were made using the Student--Newman--Keuls test. We defined the global PSLR at the baseline as the normal state and considered the values at 3 weeks and 6 months after the final cycle of chemotherapy as the test values. The values for global PSLR of the heart in breast cancer patients were determined from receiver operating characteristic (ROC) curve analysis. Yoden's index was used to determine the cut-off point with the best composite of specificity and sensitivity. Correlations between the global PSLR and LVEF, E, A, E/A, e'~sep~, a'~sep~, e'~lat~, a'~lat~, E/ e'~sep~, E/ e'~lat~, and cumulative dose of anthracycline were determined by Spearman's correlation.

Reproducibility and repeatability {#s4_5}
---------------------------------

Intraobserver and interobserver variability for global PSLR were determined by repeating measurements in all enrolled breast cancer patients. For the second intraobserver measurements, the observer was ''blinded'' to results of the initial measurements.

CONCLUSIONS {#s5}
===========

In the present study, we found that patients experienced cardiac diastolic and systolic dysfunction after anthracycline-based chemotherapy, and the cardiotoxicity of epirubicin-based chemotherapy may be stronger than that of therarubicin-based chemotherapy. The PSLR represents a new parameter that can be used for detection of cardiotoxicity in breast cancer patients after anthracycline-based chemotherapy.
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LV

:   Left ventricular

LVEF

:   Left ventricular ejection fraction

TDI

:   Tissue Doppler imaging

STE

:   Speckle tracking echocardiography

CMRI

:   Cardiac magnetic resonance imaging

LR

:   Longitudinal rotation

PSLR

:   Peak systolic longitudinal rotation

GLS

:   Global longitudinal strain

IVSd

:   Interventricular septum thickness at end-diastole

LVPWd

:   Left ventricular posterior wall thickness at end-diastole

LVDd

:   Left ventricular diameter at end-diastole

LVSd

:   Left ventricular diameter at end-systole

LVEDV

:   Left ventricular end-diastolic volume

LVESV

:   Left ventricular end-systolic volume
